The multiple sleep latency test was developed in 1978. While it is still the standard test used for the diagnosis of central disorders of hypersomnolence, its interpretation is complex and many factors can affect the validity of its results. In this podcast, Dr. Michael Silber discusses the practical use of the MSLT in 2024.

Cognitive behavioral therapy is the first-line therapy recommended for chronic insomnia. What does it comprise and who should teach it? Is Internet-based therapy available and effective? In this podcast, Dr. Mark Hansen discusses practical use of CBT-I for healthcare practitioners.

The search for the perfect hypnotic continues. In this podcast, Dr. Bhanu Kolla discusses the new dual orexin receptor antagonists, antidepressants and other agents used to treat insomnia.

The Z drugs are the most commonly prescribed hypnotics but are widely misunderstood. In this podcast, Dr. Bhanu Kolla discusses truth and myths for the clinician prescribing these drugs.

All of us who treat restless legs realize that current therapies are far from perfect. In this podcast, Dr. Michael Silber discusses possible future approaches, some already starting to be available.

Many physicians are reluctant to prescribe even low-dose opioids for chronic problems such as refractory restless legs. But opioid therapy can be life transforming for the correct patient. In this podcast, Dr. Michael Silber discusses the appropriate use of opioids for patients with restless legs refractory to other medications.

Patients are still presenting to sleep specialists on high doses of dopamine agonists with intense augmentation and profound insomnia. In this podcast, Dr. Michael Silber discusses how to manage patients with this distressing problem.

How do we define low iron stores in restless legs? In this podcast, Dr. Michael Silber discusses diagnosis of iron deficiency and how oral and intravenous iron should be administered in restless legs syndrome.

The last few years have shown a major change in first-line management of restless legs. In this podcast, Dr. Michael Silber discusses why gabapentinoids are now first-line therapy rather than dopamine agonists, how they are used, and whether there is any role still for the dopaminergic drugs.